India’s pharmaceutical sector is entering a defining phase in its evolution. For decades, the country has been recognised globally for its scale, reliability and quality in supplying medicines to the world.
GLENN SALDANHA
The next chapter, however, is about moving beyond scale — towards science-led innovation, advanced manufacturing and globally integrated research ecosystems.
Enabling this transition requires regulatory systems that evolve alongside national ambition.
Over the past few years, India has begun demonstrating precisely that shift. A series of pragmatic reforms in the pharmaceutical regulatory framework signals a broader policy recognition that effective regulation becomes enabling infrastructure for growth, innovation, and public health.
At the same time, regulators carry a complex responsibility of balancing innovation, patient safety and access at national scale. As the pharmaceutical sector grows in scientific depth and global reach, that balancing act becomes even more critical.
At the centre of this transition is the Central Drugs Standard Control Organisation (CDSCO), operating under the Ministry of Health and Family Welfare. Through targeted policy measures, the regulator has begun aligning oversight more closely with risk and outcomes, maintaining rigour where patient safety demands it while simplifying processes where procedural requirements add limited public health value.
This is not deregulation — it is regulatory maturity.
Process density to policy precision
Highly regulated industries depend on clear rules, predictable timelines and consistent oversight. Yet, over time, regulatory systems can accumulate layers of procedure that outlive their original purpose. When that happens, compliance risks becoming process-heavy without necessarily improving safety outcomes.
Source : Magzter
